Upregulation of FTX expression is associated with a poor prognosis and contributes to the progression of thyroid cancer

Wang,Ping; Zhang,Yongming; Wang,Wenping; Jiang,Huimin

doi:10.3892/ol.2021.12933

Upregulation of FTX expression is associated with a poor prognosis and contributes to the progression of thyroid cancer

Authors:
- Ping Wang
- Yongming Zhang
- Wenping Wang
- Huimin Jiang
View Affiliations

Affiliations: Department of Endocrinology, Anhui No. 2 Provincial People's Hospital, Hefei, Anhui 230041, P.R. China, Department of Hematology, Anhui No. 2 Provincial People's Hospital, Hefei, Anhui 230041, P.R. China
Published online on: July 18, 2021 https://doi.org/10.3892/ol.2021.12933
Article Number: 672
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The dysregulated expression of long non‑coding RNA FTX transcript X inactive specific transcript regulator (FTX) has been reported to be involved in the tumorigenesis of multiple cancer types. However, to the best our knowledge, its function and clinical value in thyroid cancer remain unclear. The present study aimed to determine the potential role of FTX in the development and progression of thyroid cancer. Reverse transcription‑quantitative PCR analysis revealed that the expression levels of FTX were upregulated in thyroid cancer tissues and cell lines compared with those in normal tissues and cell lines, respectively. Survival analysis demonstrated that patients with upregulated FTX expression had a lower survival rate. Functional experiments revealed that the knockdown of FTX inhibited proliferation, cell cycle progression, migration and invasion, and induced apoptosis in thyroid cancer cells, while FTX overexpression accelerated proliferation, migration and invasion, and alleviated apoptosis in thyroid cancer cells. In addition, FTX knockdown significantly inhibited tumor growth in vivo. Furthermore, in thyroid cancer cells, FTX was identified to positively regulate the expression levels of TGF‑β1, which is known to play an important regulatory role in tumor metastasis. In conclusion, the findings of the present study suggested that FTX may accelerate thyroid cancer progression via regulation of cellular activities, including cell proliferation, migration, invasion and apoptosis. Thus, FTX may represent a potential biomarker for the diagnosis, treatment and prognosis of thyroid cancer.

View Figures

View References

1	Segev DL, Umbricht C and Zeiger MA: Molecular pathogenesis of thyroid cancer. Surg Oncol. 12:69–90. 2003. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Sipos JA and Mazzaferri EL: Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 22:395–404. 2010. View Article : Google Scholar : PubMed/NCBI
4	Janovitz T and Barletta JA: Clinically relevant prognostic parameters in differentiated thyroid carcinoma. Endocr Pathol. 29:357–364. 2018. View Article : Google Scholar : PubMed/NCBI
5	Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF and Heffess CS: A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer. 91:505–24. 2001. View Article : Google Scholar : PubMed/NCBI
6	Federico C, Sun J, Muz B, Alhallak K, Cosper PF, Muhammad N, Jeske A, Hinger A, Markovina S, Grigsby P, et al: Localized Delivery of Cisplatin to Cervical cancer improves its therapeutic efficacy and minimizes its side effect profile. Int J Radiat Oncol Biol Phys. 109:1483–1494. 2021. View Article : Google Scholar : PubMed/NCBI
7	Mohammad N, Singh SV, Malvi P, Chaube B, Athavale D, Vanuopadath M, Nair SS, Nair B and Bhat MK: Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Sci Rep. 5:118532015. View Article : Google Scholar : PubMed/NCBI
8	Muhammad N, Bhattacharya S, Steele R and Ray RB: Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 7:58595–58605. 2016. View Article : Google Scholar : PubMed/NCBI
9	Muhammad N, Bhattacharya S, Steele R, Phillips N and Ray RB: Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma. Clin Cancer Res. 23:3120–3128. 2017. View Article : Google Scholar : PubMed/NCBI
10	Liu H, Deng H, Zhao Y, Li C and Liang Y: LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J Exp Clin Cancer Res. 37:2792018. View Article : Google Scholar : PubMed/NCBI
11	Huang JK, Ma L, Song WH, Lu BY, Huang YB, Dong HM, Ma XK, Zhu ZZ and Zhou R: LncRNA-MALAT1 promotes angiogenesis of thyroid cancer by modulating tumor-associated macrophage FGF2 protein secretion. J Cell Biochem. 118:4821–4830. 2017. View Article : Google Scholar : PubMed/NCBI
12	Qin Y, Xue B, Liu C, Wang X, Tian R, Xie Q, Guo M, Li G, Yang D and Zhu H: NLRX1 mediates MAVS degradation to attenuate the hepatitis C virus-induced innate immune response through PCBP2. J Virol. 91:e01264–17. 2017. View Article : Google Scholar : PubMed/NCBI
13	Li B, Ren P and Wang Z: Long non-coding RNA Ftx promotes osteosarcoma progression via the epithelial to mesenchymal transition mechanism and is associated with poor prognosis in patients with osteosarcoma. Int J Clin Exp Pathol. 11:4503–4511. 2018.PubMed/NCBI
14	Zhang F, Wang XS, Tang B, Li PA, Wen Y and Yu PW: Long non-coding RNA FTX promotes gastric cancer progression by targeting miR-215. Eur Rev Med Pharmacol Sci. 24:3037–3048. 2020.PubMed/NCBI
15	Yang Y, Zhang J, Chen X, Xu X, Cao G, Li H and Wu T: LncRNA FTX sponges miR-215 and inhibits phosphorylation of vimentin for promoting colorectal cancer progression. Gene Ther. 25:321–330. 2018. View Article : Google Scholar : PubMed/NCBI
16	Liang Y and Lu H: Long noncoding RNA FTX is associated with prognosis of glioma patients. J Gene Med. 22:e32372020. View Article : Google Scholar : PubMed/NCBI
17	Jiang W, Zhang B, Sun J, Liu Y, Bi Y and Wei H: LncRNA FTX promotes the tumorigenesis of lung adenocarcinoma by targeting miR-300. Panminerva Med. Jan 24–2020.(Epub ahead of print). doi: 10.23736/S0031-0808.19.03823-0.
18	Luzón-Toro B, Villalba-Benito L, Fernández RM, Torroglosa A, Antiñolo G and Borrego S: RMRP, RMST, FTX and IPW: Novel potential long non-coding RNAs in medullary thyroid cancer. Orphanet J Rare Dis. 16:42021. View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Sun DY, Wu JQ, He ZH, He MF and Sun HB: Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-β signaling pathway. Life Sci. 235:1167912019. View Article : Google Scholar : PubMed/NCBI
21	Dai G, Sun B, Gong T, Pan Z, Meng Q and Ju W: Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling. Phytomedicine. 56:126–135. 2019. View Article : Google Scholar : PubMed/NCBI
22	Choudhari R, Sedano MJ, Harrison AL, Subramani R, Lin KY, Ramos EI, Lakshmanaswamy R and Gadad SS: Long noncoding RNAs in cancer: From discovery to therapeutic targets. Adv Clin Chem. 95:105–147. 2020. View Article : Google Scholar : PubMed/NCBI
23	Chan JJ and Tay Y: Noncoding RNA:RNA regulatory networks in cancer. Int J Mol Sci. 19:13102018. View Article : Google Scholar : PubMed/NCBI
24	Wen HL, Xu ZM, Wen D, Lin SY, Liang Y and Xie JP: Long noncoding RNAs SET-binding factor 2-antisense RNA1 promotes cell growth through targeting miR-431-5p/CDK14 axis in human papillary thyroid cancer. Kaohsiung J Med Sci. 36:808–816. 2020. View Article : Google Scholar : PubMed/NCBI
25	Li Q, Chen W, Luo R, Zhang Z, Song M, Chen W, Yang Z, Yang Y, Guo Z and Yang A: Upregulation of OIP5-AS1 predicts poor prognosis and contributes to thyroid cancer cell proliferation and migration. Mol Ther Nucleic Acids. 20:279–291. 2020. View Article : Google Scholar : PubMed/NCBI
26	Zheng W, Tian X, Cai L, Shen YM, Cao QS, Yang JY and Tian GY: LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer. Eur Rev Med Pharmacol Sci. 23:10443–10452. 2019.PubMed/NCBI
27	Huo X and Wang H, Huo B, Wang L, Yang K, Wang J, Wang L and Wang H: FTX contributes to cell proliferation and migration in lung adenocarcinoma via targeting miR-335-5p/NUCB2 axis. Cancer Cell Int. 20:892020. View Article : Google Scholar : PubMed/NCBI
28	Zhang W, Bi Y, Li J, Peng F, Li H, Li C, Wang L, Ren F, Xie C, Wang P, et al: Long noncoding RNA FTX is upregulated in gliomas and promotes proliferation and invasion of glioma cells by negatively regulating miR-342-3p. Lab Invest. 97:447–457. 2017. View Article : Google Scholar : PubMed/NCBI
29	He X, Sun F, Guo F, Wang K, Gao Y, Feng Y, Song B, Li W and Li Y: Knockdown of long noncoding RNA FTX inhibits proliferation, migration, and invasion in renal cell carcinoma cells. Oncol Res. 25:157–166. 2017. View Article : Google Scholar : PubMed/NCBI
30	Chen H, Liu T, Ouyang H, Lin S, Zhong H, Zhang H and Yang Y: Upregulation of FTX promotes osteosarcoma tumorigenesis by increasing SOX4 expression via miR-214-5p. Onco Targets Ther. 13:7125–7136. 2020. View Article : Google Scholar : PubMed/NCBI
31	Chen Y, Gao H and Li Y: Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway. Mol Cell Endocrinol. 500:1106342020. View Article : Google Scholar : PubMed/NCBI
32	Zhang X, Liu L, Deng X, Li D, Cai H, Ma Y, Jia C, Wu B, Fan Y and Lv Z: MicroRNA 483-3p targets Pard3 to potentiate TGF-β1-induced cell migration, invasion, and epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Oncogene. 38:699–715. 2019. View Article : Google Scholar : PubMed/NCBI